TY - JOUR
T1 - The impact of CFTR modulator therapies on CF airway microbiology
AU - Rogers, Geraint B.
AU - Taylor, Steven L.
AU - Hoffman, Lucas R.
AU - Burr, Lucy D.
PY - 2020/5
Y1 - 2020/5
N2 - Major historical advances in cystic fibrosis (CF) respiratory clinical care, including mechanical airway clearance and inhaled medications, have aimed to address the consequences of cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction. In contrast, CFTR modulator therapies instead target the underlying protein defect that leads to CF lung disease. The extent to which these therapies might reduce susceptibility to chronic lung infections remains to be seen. However, by improving airway clearance, reducing the requirement for antibiotics, and in some cases, through direct antimicrobial effects, CFTR modulators are likely to result in substantial changes in CF airway microbiology. These changes could contribute substantially to the clinical benefit associated with modulator therapies, as well as providing an important indicator of treatment efficacy and residual pathophysiology. Indeed, the widespread introduction of modulator therapies might require us to re-consider our models of CF airway microbiology.
AB - Major historical advances in cystic fibrosis (CF) respiratory clinical care, including mechanical airway clearance and inhaled medications, have aimed to address the consequences of cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction. In contrast, CFTR modulator therapies instead target the underlying protein defect that leads to CF lung disease. The extent to which these therapies might reduce susceptibility to chronic lung infections remains to be seen. However, by improving airway clearance, reducing the requirement for antibiotics, and in some cases, through direct antimicrobial effects, CFTR modulators are likely to result in substantial changes in CF airway microbiology. These changes could contribute substantially to the clinical benefit associated with modulator therapies, as well as providing an important indicator of treatment efficacy and residual pathophysiology. Indeed, the widespread introduction of modulator therapies might require us to re-consider our models of CF airway microbiology.
KW - Airway microbiome
KW - CFTR modulators
KW - Lung infection
UR - http://www.scopus.com/inward/record.url?scp=85070385140&partnerID=8YFLogxK
U2 - 10.1016/j.jcf.2019.07.008
DO - 10.1016/j.jcf.2019.07.008
M3 - Review article
AN - SCOPUS:85070385140
SN - 1569-1993
VL - 19
SP - 359
EP - 364
JO - Journal of Cystic Fibrosis
JF - Journal of Cystic Fibrosis
IS - 3
M1 - JCF-01859
ER -